Schrödinger Jumps 6.1% Amid Sector-Wide Rally
Schrödinger (SDGR) shares surged 6.1% to $32.16 on Monday, participating in a broad sector-wide rally that lifted health information services stocks. The gain appears to be driven by macro factors like sector rotation or positive sentiment rather than company-specific news, with other peers also seeing notable gains. Investors will be watching for fundamental catalysts to sustain this momentum.
Schrodinger Inc. Stock Grades | SDGR
This article provides stock grade information for Schrodinger Inc. (SDGR), including analyst ratings, key financial metrics, and company overview. It shows an average price target of $21.43 from 7 ratings and highlights the company's focus on chemical simulation software for the pharmaceutical industry. The stock's performance metrics, such as YTD and 12-month changes, volume, market value, and short interest, are also detailed.
SDGR Stock: Schrödinger Hopes Its AI Agent Can Transform Drug Discovery
Schrödinger (SDGR) leverages its physics-based software platform, molecular simulation, machine learning, and AI to transform drug discovery and materials science. The company's recent Q2 2026 results highlighted a strategic shift towards hosted software, the launch of its agentic AI product Bunsen, and significant drug discovery revenue driven by a milestone from Eli Lilly's acquisition of Ajax Therapeutics. Bunsen, designed as an AI co-scientist, is expected to be a major growth driver, with a strategic agreement already signed with Bristol Myers Squibb.
Schrodinger stock hits 52-week high at 31.69 USD
Schrodinger Inc. (SDGR) stock recently hit a 52-week high of $31.69, reflecting a 167% 6-month gain and 51.2% 1-year increase. Despite being deemed potentially overvalued by InvestingPro, the computational drug discovery firm surpassed Q2 2026 earnings and revenue forecasts and received a "Neutral" rating from UBS.
Schrodinger stock hits 52-week high at 31.69 USD By Investing.com
Schrodinger Inc. (SDGR) has hit a new 52-week high of $31.69, reflecting significant investor confidence and strong performance. The company, a computational drug discovery firm, has seen a 167% gain over six months and a 51.2% increase over one year. Recent financial results show adjusted profit exceeding forecasts, revenue surpassing projections, and a 27% rise in annual contract value.
Schrodinger stock hits 52-week high at 31.69 USD By Investing.com
Schrodinger Inc. (SDGR) has reached a 52-week high of $31.69, reflecting significant investor confidence with a 6-month gain of 167% and a 1-year increase of 51.2%. Despite trading above its Fair Value, the company recently surpassed Q2 2026 earnings and revenue forecasts, achieving an adjusted profit of $0.08 per share. UBS initiated coverage with a Neutral rating, projecting 16% software growth and positive EBITDA by fiscal year 2028.
EBITDA margin % of Schrodinger, Inc. – HAN:43Z
This article provides financial data specifically on the EBITDA margin percentage for Schrodinger, Inc. (HAN:43Z) traded on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of publication and offers various tools and resources available on the TradingView platform for financial analysis.
Free cash flow per share of Schrodinger, Inc. – HAN:43Z
This page from TradingView displays the free cash flow per share for Schrodinger, Inc. (HAN:43Z) on the Hannover Stock Exchange. It provides financial data and indicates that the market is currently closed with no trades. The content is part of TradingView's extensive financial tools, offering market data and analysis features.
Price to book forward of Schrodinger, Inc. – HAN:43Z
This article provides a financial overview of Schrodinger, Inc. (HAN:43Z) on the Hannover Stock Exchange, specifically focusing on its price-to-book forward ratio. The content indicates that the market was closed with no trades at the time of publication. It highlights basic financial data availability and references various data providers.
These ten healthcare stocks posted the biggest September gains
This article identifies the top 10 performing healthcare stocks for September 2026, highlighting significant gains in various sub-sectors like Biotechnology and Health Care Technology. Kodiak Sciences Inc. led with a 138.39% increase, followed by GRAIL, Inc. and Schrödinger, Inc. The list also notes several stocks with "Strong Buy" Quant Ratings from Seeking Alpha.
43Z.SG Interactive Stock Chart | Schrodinger Inc. Stock
The article displays an interactive stock chart for Schrodinger Inc. (43Z.SG) on Yahoo Finance. It shows the stock's performance, indicating a price of EUR 27.54 with a 4.04% increase at the close on September 30.
Schrödinger Drops 7.6% Amid Sector-Wide Selling
Schrödinger shares dropped 7.6% to $28.36 due to sector-wide selling, not company-specific news. Similar declines in peer companies like HTFL and WAY suggest a coordinated move away from the health information services sector. Investors are advised to monitor sector performance to determine if this is a short-term correction or a broader reassessment of valuations.
Precision Trading with Schrodinger Inc. (SDGR) Risk Zones
This article provides a precision trading analysis for Schrodinger Inc. (SDGR), highlighting its strong near and mid-term sentiment and upside potential. It outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also details multi-timeframe signal strengths and support/resistance levels generated by AI models.
Options at $4.34 become shares sold near $30 for Schrodinger (SDGR) insider
Schrodinger executive Karen Akinsanya exercised 31,599 stock options at $4.34 per share and subsequently sold all resulting shares at prices of $28.00 and $30.00 per share. These transactions were carried out on September 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, Akinsanya retains a remaining option position of 11,599 shares and 63,545 unvested Restricted Stock Units (RSUs).
Schrodinger president Karen Akinsanya sells $927,970 in company stock
Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer at Schrodinger, Inc. (NASDAQ:SDGR), sold 31,599 shares of company stock for $927,970 on September 17, 2026. This sale, executed via a Rule 10b5-1 trading plan, occurred after she exercised stock options for the same number of shares at a lower price. The company recently reported strong Q2 2026 earnings, surpassing Wall Street expectations, with adjusted profit and revenue both exceeding estimates.
Schrodinger president Karen Akinsanya sells $927,970 in company stock By Investing.com
Karen Akinsanya, President at Schrodinger, Inc., sold 31,599 shares of company stock worth $927,970 on September 17, 2026, after exercising stock options. This sale occurred while the stock was near its 52-week high and appears overvalued according to InvestingPro. The company recently reported strong Q2 2026 earnings, exceeding Wall Street expectations, and UBS initiated coverage with a "Neutral" rating.
Schrodinger Inc (SDGR) Shares Fall 4.0% -- GF Value Says Still Overvalued
Schrodinger Inc (SDGR) shares recently dropped 4.0% to $29.01, and GuruFocus's GF Value estimates the stock is 17.5% overvalued at $24.69. The company has a GF Score of 70/100, indicating above-average quality, but struggles with profitability and has seen significant insider selling without any buying activity. Investors are cautioned due to the overvaluation, weak profitability, and lack of insider confidence.
Schrödinger (SDGR) Stock Surges 60% but $37 Resistance Could Test the Rally as Mixed Fundamentals Raise Fresh Risks
Schrödinger's (SDGR) stock surged approximately 60% this week, climbing above $30, despite underlying concerns about slowing software metrics and a reduced drug pipeline. The company's software business shows signs of deterioration, and its drug development strategy has become more cautious, relying on partnerships. While the balance sheet has improved, the rally faces significant challenges from mixed fundamentals and execution risks, with key resistance levels at $37 and $60.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 17, 2026
Schrödinger, Inc. (Nasdaq: SDGR) announced that on September 13, 2026, it granted restricted stock units (RSUs) for 2,243 shares to three new employees as a material inducement for their employment. These grants, made under the company's 2021 Inducement Equity Incentive Plan, vest over four years. The RSUs are subject to award agreements and comply with Nasdaq Listing Rule 5635(c)(4).
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. reported inducement grants of restricted stock units (RSUs) to three new employees on September 13, 2026, totaling 2,243 shares. These grants were made under the company's 2021 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting after 12 months and the remainder in equal yearly installments over the subsequent three years.
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
Schrodinger (SDGR) shares recently surged 12.1% due to investor optimism over the formation of Tectora, a new biotechnology company co-founded by Schrodinger, New Enterprise Associates, and RA Capital Management. Tectora will focus on immunology and inflammation therapies, leveraging Schrodinger's computational platform. Analysts anticipate a quarterly loss of $0.66 per share for Schrodinger, though earnings estimates have been revised upward, suggesting potential for continued stock appreciation.
Schrodinger Inc stock hits 52-week high at 23.06 USD
Schrodinger Inc (SDGR) stock has reached a new 52-week high of $23.06, reflecting an 18.58% 1-year change and a 66% return over the past six months. Despite trading above its Fair Value, indicating it may be overvalued, this milestone highlights strong investor confidence and potential growth. The company recently surpassed Q2 2026 earnings forecasts and saw UBS initiate coverage with a Neutral rating and a $19.00 price target.
Understanding the Setup: (SDGR) and Scalable Risk
This article analyzes Schrodinger Inc. (NASDAQ: SDGR) using AI models, identifying weak near-term sentiment and highlighting a lack of resistance levels above the current price. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, along with multi-timeframe signal analysis. The report also notes the company's weak long-term signal strength.
Schrödinger introduces Tectora Therapeutics
Schrödinger Inc. has announced the launch of Tectora Therapeutics, a new biotechnology company co-founded with New Enterprise Associates (NEA) and RA Capital Management. This new venture will focus on developing innovative oral therapies specifically for immunology and inflammation.
Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc.
Tectora Therapeutics Inc. has secured $55 million in a funding round on September 9, 2026. The investment saw participation from new investors New Enterprise Associates, Inc., RA Capital Management, L.P., and Schrödinger, Inc. The company issued convertible preferred shares as part of this transaction.
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Schrödinger, Inc. has co-founded Tectora Therapeutics with New Enterprise Associates (NEA) and RA Capital Management, focusing on developing therapies for immunology and inflammation. Tectora closed a $55 million Series A investment and will leverage Schrödinger’s computational platform to advance two early-stage small molecule programs. This collaboration continues Schrödinger's strategy of partnering to accelerate drug discovery and build biotechnology companies.
Schrödinger to Present at Morgan Stanley Global Healthcare Conference 2026
Schrödinger, Inc. (Nasdaq: SDGR) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 1:05 p.m. E.T. A live webcast of the presentation will be available on the "Investors" section of Schrödinger’s website, with an archive accessible for approximately 90 days following the event. The company uses its computational platform to accelerate molecular discovery for drug development and materials design, leveraging over 30 years of R&D.
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
Schrödinger, Inc. announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 1:05 p.m. E.T. A live webcast of the presentation will be available on the "Investors" section of Schrödinger's website and will be archived for approximately 90 days. Schrödinger uses its computational platform to discover novel molecules for drug development and materials design.
Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR
Tejara Capital Ltd has initiated a new position in Schrodinger, Inc. (NASDAQ:SDGR) valued at $4.55 million, acquiring 280,202 shares, which represents about 0.38% of the company. Despite mixed analyst sentiment, with an average "Hold" rating, Schrodinger's recent quarterly results exceeded expectations, reporting revenues of $58.89 million and earnings of $0.08 per share. The stock has seen significant institutional investment, with other firms also adjusting their stakes.
Schrodinger Inc (SDGR) News, Articles, Events & Latest Updates
This article provides a compilation of recent news and updates regarding Schrodinger Inc (SDGR). Key highlights include their Q2 2026 financial results which surpassed estimates, the announcement of a strategic collaboration with Bristol Myers Squibb to deploy their AI co-scientist Bunsen, and the launch of Bunsen for molecular discovery. The company also reported inducement grants of restricted stock units to new employees on multiple occasions.
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $24
BMO Capital has reiterated its Buy rating for Schrodinger (SDGR.US) and maintained its price target at $24. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - August 14, 2026
Schrödinger, Inc. (Nasdaq: SDGR) announced that on August 12, 2026, it granted restricted stock units (RSUs) for 3,315 shares to two new employees. These grants were made under the company’s 2021 Inducement Equity Incentive Plan, approved by the compensation committee, as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting after 12 months of continuous service, and the remainder vesting in equal yearly installments over the subsequent three years.
SDGR Assumed by UBS -- Price Target Raised to $19.00
UBS has assumed coverage on Schrodinger (SDGR), raising its price target from $13.00 to $19.00, while maintaining a Neutral rating. GuruFocus indicates SDGR is currently undervalued by 29.0% with a GF Value™ of $25.03 and has a moderately favorable GF Score™ of 73/100, though profitability remains a challenge. Insider activity shows no recent buying, suggesting caution for investors despite the stock's potential.
UBS Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $19
UBS has reiterated its Hold rating on Schrodinger (SDGR.US) and maintained its target price at $19. This indicates that the firm does not anticipate significant upward or downward movement for the stock in the near term, based on its current analysis.
UBS initiates Schrodinger stock coverage with neutral rating
UBS has initiated coverage on Schrodinger Inc. (NASDAQ:SDGR) with a Neutral rating and a $19.00 price target. The firm is awaiting greater traction in Schrodinger's shift to a software-centric drug discovery model before adopting a more active stance, noting the absence of clear catalysts in the next 12 months. Despite a strong 62% return over the past six months, the company remains unprofitable, though it recently reported exceeding Q2 2026 earnings expectations with positive adjusted profit and revenue.
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating
UBS has adjusted its price target for Schrodinger, Inc. (SDGR) to $19 from $13, while maintaining a Neutral rating on the stock. This update comes after several recent news items for Schrodinger, including their Q2 2026 earnings call and revenue report, and new strategic collaborations. Schrodinger is a developer of a physics-based computational platform for drug discovery.
Two New Schrödinger Hires Get Stock Awards Vesting Over Four Years
Schrödinger, Inc. (Nasdaq: SDGR) reported granting restricted stock units (RSUs) for 3,315 shares of common stock to two new employees on August 12, 2026. These inducement grants, made under Nasdaq Listing Rule 5635(c)(4), will vest over four years, with 25% vesting after 12 months of continuous service and the remainder in equal yearly installments over the subsequent three years. This aims to attract and retain talent in line with the company's 2021 Inducement Equity Incentive Plan.
UBS initiates Schrodinger stock coverage with neutral rating
UBS has initiated coverage on Schrodinger Inc. (NASDAQ:SDGR) with a Neutral rating and a $19.00 price target. The firm notes Schrodinger's strong 62% return over the past six months despite unprofitability and projects future software growth, but seeks more traction in the company's software-centric drug discovery model and clearer catalysts. UBS also highlighted Schrodinger's recent strong Q2 2026 earnings, which surpassed Wall Street expectations with an adjusted profit of $0.08 per share and significant revenue growth.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. announced inducement grants of restricted stock units (RSUs) for 3,315 shares to two new employees on August 12, 2026. These grants, approved by the compensation committee, were a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% after 12 months and the remainder in yearly installments over the subsequent three years.
Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside
Schrodinger, Inc.'s average stock price target has increased to $21.83, up from $20.57, according to six analysts. This new target suggests an 18% potential upside from the August 13 closing price, with individual forecasts ranging from $17 to $30 per share. The consensus rating for the stock remains a "Buy," with five out of six analysts recommending a Buy and one a Hold.
Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 Profitability - Has The Bull Case Changed?
Schrödinger (SDGR) saw its stock rise by 19.2% following a significant Q2 2026 earnings report that showed a swing to profitability and a new agreement with Bristol Myers Squibb (BMS). BMS will deploy Schrödinger's AI co-scientist "Bunsen" across its research organization, signifying a deeper integration of Schrödinger's physics-based and AI discovery tools into large pharmaceutical workflows. This development strengthens the investment thesis that Schrödinger's technology can become a core component in drug discovery, potentially leading to more consistent profitability.
Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR
Quantinno Capital Management LP has acquired 174,095 shares of Schrodinger, Inc. (NASDAQ:SDGR) for approximately $1.98 million during the first quarter. This investment is part of a trend where several institutional investors have increased their holdings in Schrodinger, with institutions now owning 79.05% of the stock. Despite reporting better-than-expected quarterly earnings and revenue, Schrodinger remains unprofitable, holding a consensus "Hold" rating from analysts.
Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 Profitability - Has The Bull Case Changed?
Schrödinger (SDGR) saw its stock rise by 19.2% following the announcement of its Q2 2026 profitability and an expanded AI partnership with Bristol Myers Squibb. The agreement integrates Schrödinger's "Bunsen" AI co-scientist into Bristol Myers Squibb's research, bolstering the company's investment thesis that its AI and physics-based tools will become deeply embedded in large pharma workflows. This development is seen as a significant catalyst for Schrödinger's long-term software growth story, despite potential ongoing margin pressure from R&D investments.
Schrödinger Unveils Bunsen, an AI Co-Scientist for Enhanced Molecular Discovery
Schrödinger, Inc. has launched Bunsen, an AI co-scientist designed to assist researchers in molecular discovery by leveraging AI and physics-based simulations. This tool aims to streamline scientific workflows, allowing for more hypotheses to be evaluated and accelerating discovery decisions. Bunsen operates on a computing ecosystem co-engineered with NVIDIA and Google Cloud, providing scalable solutions for large-scale molecular discovery.
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Schrödinger, Inc. (NASDAQ:SDGR) saw its shares surge 20% after exceeding second-quarter expectations with revenues of US$59m and a surprise statutory profit of US$0.08 per share. Analysts have updated their 2026 forecasts, projecting revenues of US$240.3m and a reduced loss of US$1.61 per share, indicating increased optimism despite no change to the average price target of US$20.57. However, future revenue growth is expected to slow significantly compared to the broader industry.
Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR
Dimensional Fund Advisors LP significantly reduced its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 12.7% in the first quarter, selling 128,983 shares. Despite this, the fund still held 883,648 shares worth $10.0 million. Schrodinger's latest quarterly results surpassed expectations with an EPS of $0.08 against a projected $0.41 loss and revenue of $58.89 million, although the company remains unprofitable.
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Schrödinger, Inc. (NASDAQ:SDGR) saw its shares surge 20% after reporting strong second-quarter results, with revenues exceeding expectations and a surprise statutory profit. Analysts have increased their optimism for the company's future, particularly reducing loss per share forecasts for 2026, though the consensus price target remains unchanged at US$20.57. Despite these upgrades, revenue growth is projected to slow and underperform the wider industry.
Schrödinger, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Schrödinger, Inc. (NASDAQ:SDGR) recently surpassed its earnings expectations, leading to a positive market reaction. Analysts have since upgraded their price targets and revenue forecasts for the company, indicating increased confidence in its future performance. The article delves into these revised expectations and what they imply for Schrödinger's stock.
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Schrödinger, Inc. (NASDAQ:SDGR) saw its shares surge 20% after reporting strong second-quarter results, with revenues of US$59m and a surprise statutory profit of US$0.08 per share. Analysts have updated their 2026 forecasts, now expecting US$240.3m in revenue and a reduced loss per share of US$1.61, indicating increased optimism despite a projected revenue decline compared to the industry. The consensus price target remains at US$20.57.
Schrodinger (NASDAQ:SDGR) Raised to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Schrodinger (NASDAQ:SDGR) from a "strong sell" to a "hold" rating, aligning with the broader analyst consensus of "Hold" and a $20.25 price target. This upgrade follows Schrodinger's better-than-expected quarterly results, reporting $0.08 EPS against a projected $0.41 loss, and a 7.5% year-over-year revenue increase to $58.89 million. The company, which opened at $18.16 with a $1.34 billion market cap, also saw BlackRock acquire a new $171 million position, contributing to institutional investors holding approximately 79.05% of the stock.
